CQ-16

• Description:

  CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA) . CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM) . (Pink: PSMA Ligand (HY-139840) ; Black: Linker (HY-W037980) ; Blue: PARP Inhibitor (HY-10162) ) [1]

• UNSPSC:

  12352005

• Target:

  PARP; PSMA

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cq-16.html

• Smiles:

  O=C1NN=C (C2=CC=CC=C21) CC3=CC=C (C (C (N4CCN (CC4) C (C5 (NC (CCC (NCCCC[C@H] (NC (N[C@H] (C (O) =O) CCC (O) =O) =O) C (O) =O) =O) =O) CC5) =O) =O) =C3) F

• Molecular Formula:

  C40H47FN8O12

• Molecular Weight:

  850.85

• References & Citations:

  [1]Chen Q, et al. A Prostate-Specific Membrane Antigen-Targeting Small Molecule–Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib[J]. Journal of Medicinal Chemistry, 2024.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  3024354-59-1